Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA OKs intentional genomic alteration in pigs — with potential therapeutic applications

By Brian Buntz | December 15, 2020

Pigs

Image from Pascal Debrunner on Unsplash

The FDA has approved an intentional genomic alteration (IGA) in a line of domestic pigs known as GalSafe. The decision marks the first time the agency has signed off on a biotechnology product for both food applications and potential therapeutic use.

The news “represents a tremendous milestone for scientific innovation,” said FDA Commissioner Dr. Stephen M. Hahn in a statement. “As part of our public health mission, the FDA strongly supports advancing innovative animal biotechnology products that are safe for animals, safe for people, and achieve their intended results.”

The GalSafe pig alteration removes the alpha-gal sugar (galactose-α-1,3-galactose) on the surface of pig cells.

A segment of the population has a mild to severe allergic reaction to this sugar molecule; the reaction is called alpha-gal syndrome. The sugar is found in many mammals, as well as some medications and vaccines.

The GalSafe pigs could be a source of biomaterials for use in individuals with alpha-gal syndrome. Examples include the blood-thinning medication heparin. Surgeons could also potentially use tissues and organs from GalSafe pigs in xenotransplants. The alpha-gal sugar possibly contributes to xenotransplantation rejection.

The genetically modified pigs also have several human genes, including a gene that makes a protein known as CD46 involved in the human immune system.

The prevalence of alpha-gal syndrome (AGS), also known as alpha-gal allergy, is currently unknown, although CDC believes ticks may cause the condition.

FDA also determined that meat from GalSafe pigs is safe for consumption and confirmed that they could not detect alpha-gal sugar in the meat.

GalSafe pigs developer Revivicor, however, did not provide data to FDA indicating that the meat could eliminate or prevent food allergies.

The agency did not evaluate the GalSafe pig line for its potential for xenotransplantation products. Such a use would require the developer to submit an additional application to the FDA.

The company states that it ultimately aims to provide human-compatible cells to treat disease and serve as a source for transplants.

Researchers first developed a genetically modified pig lacking the gene associated with alpha-gal sugar. In experiments, the porcine organs survived for months rather than minutes in nonhuman primates.

The first focus of the product developer will be culinary rather than medical. The vendor plans on selling meat from GalSafe pigs by mail order.

PETA senior vice president Kathy Guillermo released a statement regarding the news. “The genetic manipulation of pigs to serve as interspecies spare-parts bins and more palatable dinner entrées for humans is the apex of arrogance and cruelty,” she said. “Pigs aren’t apples. They’re sentient beings, and fiddling with their genes to produce different varieties that suit our needs and changing tastes is violence, not innovation. Pigs’ genetic material belongs to pigs, and it should be considered inviolate.”

Revivcor is a sister company to PPL Therapeutics, which produced Dolly the Sheep, the first mammal cloned from an adult stem cell.

Comments

  1. LucyP says

    December 15, 2020 at 9:42 pm

    This is not happy news for pigs. It simply opens more doors for them to be exploited, abused, and killed by humans. These smart, sensitive beings deserve to be respected and left in peace, not genetically manipulated for our convenience.

    Reply
  2. Kim Marie says

    December 15, 2020 at 9:47 pm

    Enough of this Frankenscience. Leave animals in peace!

    Reply
  3. Shellatthebeach says

    December 16, 2020 at 2:34 pm

    Ugh, this is repulsive. Stop thinking up new ways to torture animals and focus on progressive testing methods like using donated human tissues and computer modeling.

    Reply
  4. Ed F. says

    January 6, 2021 at 7:31 pm

    A solution to a problem that we don’t yet know the prevalence for. What are the chances for unintended consequences in these pigs? Just like GMO plants, once this gets out of the lab, where are the controls to keep these pigs separated from the other non-modified ones? How many generations of these modified pigs need to be studied before we see what these changes might have in the long run? While we won’t have to worry about the insects moving the pig’s genetically modified genes around (or do we?), Nature will find ways to cross breed and then these modifications will be everywhere! No going back! Finally, who is studying the humans who consume these pigs?

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Pharma image
Here’s what molecular shape can tell you about pharma innovation
Remdesivir
3 notable types of innovative drugs from 2020
Phastar
Phastar wins investment from Charterhouse Capital Partners

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards